{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-007206","form_type":"8-K","ticker":"AEMD","cik":"0000882291","company_name":"AETHLON MEDICAL INC","filed_at":"2026-09-17T12:03:36+00:00","discovered_at":"2026-09-17T12:05:00.450999+00:00","generated_at":"2026-09-17T12:05:17.158866+00:00","sec_items":["1.01","5.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Aethlon Medical to merge with North Immunology in $150M all-stock deal; $180M PIPE backs NOR-101","bullets":["All-stock merger values North Immunology at $150M and Aethlon at $16.5M; closing expected by June 17, 2027.","North Immunology stockholders to own ~95.25% of combined company; Aethlon holders ~4.75%.","Oversubscribed $180M private placement ($146M cash + $34M notes) funds operations into 2H 2028.","NOR-101 (IL-13 x IL-18 bispecific) for atopic dermatitis: Phase 1a Q1 2027, Phase 1b/2b data 2028.","Legacy Aethlon assets to receive contingent value rights (CVRs) with no guaranteed payments."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-007206","json":"https://secwatch.observer/filing/0001683168-26-007206.json","markdown":"https://secwatch.observer/filing/0001683168-26-007206.md","text":"https://secwatch.observer/filing/0001683168-26-007206.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882291/000168316826007206/0001683168-26-007206-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882291/000168316826007206/aethlon_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-17T12:05:17.158866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}